A Phase 1/2 interventional study of Magnesium sulfate and Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 6 Hours to 72 Hours. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Sohag University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on mechanical ventilation.
Persistent pulmonary hypertension of newborn (PPHN) is a serious condition that results from failure of the normal postnatal circulatory transition and is associated with significant mortality and morbidity. Advanced medical treatment, such as inhaled nitric oxide (iNO), high-frequency ventilation (HFV), and extracorporeal membrane oxygenation (ECMO) are commonly not available in developing countries. Intravenous magnesium sulfate has been shown to alleviate pulmonary hypertension but is associated with systemic hypotension and is less effective compared with iNO and sildenafil. Nebulized magnesium sulfate has been reported to be more effective and safer compared with intravenous magnesium sulfate in treating neonates with PPHN on mechanical ventilation. Combined nebulized magnesium and sildenafil has been studied in a small trial on spontaneously breathing neonates with PPHN but not on those connected to mechanical ventilation.
The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe PPHN on mechanical ventilation. We hypothesize that neonates with severe PPHN connected to mechanical ventilation could benefit from taking continuous nebulization of magnesium sulfate combined besides sildenafil.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
This study's planned enrollment of 40 is close to the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.
Browse Persistent Fetal Circulation Syndrome studies →Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nebulized magnesium sulfate and oral sildenafil
Drug: Magnesium sulfate · Drug: Sildenafil Citrate
Nebulized placebo (isotonic saline) and oral sildenafil
Drug: Sildenafil Citrate · Other: Isotonic saline
Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
Also known as: MgSO4
Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
Also known as: Viagra
Nebulized isotonic saline (4 ml) every 15 minutes
Also known as: 0.9% NaCl
Change in Oxygenation index (OI)
OI will be calculated using the following formula: OI = \[(FiO2 × MAP) / PaO2\] (FiO2, fraction of inspired oxygen expressed in %; MAP, mean airway pressure in cmH2O/mmHg; and PaO2, partial pressure of arterial oxygen in mmHg).
Time frame: From baseline to 2, 6, 12, and 24 hours following study drug administration
Change in Mean arterial blood pressure (MABP)
Time frame: From baseline to 2, 6, 12, and 24 hours following study drug administration.
Change in Vasoactive Inotropic Score (VIS)
The VIS will be calculated using the following formula: VIS = dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 × epinephrine dose (µg/kg/min) + 100 × norepinephrine dose (µg/kg/min) + 10 × milrinone dose (µg/kg/min) + 10,000 × vasopressin dose (U/kg/min).
Time frame: From baseline to 2, 6, 12, and 24 hours following study drug administration.
Change in Pulmonary artery systolic pressure (PASP)
PASP will be estimated by echocardiography using the modified Bernoulli equation: PASP = (TRJV2 × 4) + RAP (TRJV, tricuspid regurgitation jet velocity; RAP, right atrial pressure).
Time frame: From baseline to 24 hours after study drug administration
Change in Serum magnesium level
Time frame: From baseline to 24 hours after study drug administration
Plan to share: Yes — Unidentified individual participant data will be available from the principal investigator upon reasonable request
Supporting information: Study protocol
Time frame: Three years after publication of the study results
Access criteria: Unidentified individual participant data can be requested from the principal investigator
Started Jun 2021 (actual). Primary completion is estimated for Apr 2025, 46 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magnesium Sulfate
Persistent Fetal Circulation Syndrome →